4//SEC Filing
Lebwohl David 4
Accession 0001209191-23-001492
CIK 0001652130other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 8:33 PM ET
Size
7.7 KB
Accession
0001209191-23-001492
Insider Transaction Report
Form 4
Lebwohl David
EVP, Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2023-01-01+3,187→ 28,261 total - Exercise/Conversion
Restricted Stock Unit
2023-01-01−3,187→ 6,376 totalFrom: 2023-01-01Exp: 2031-03-02→ Common Stock (3,187 underlying)
Footnotes (3)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]Includes 105 and 231 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022 and December 31, 2022, respectively.
- [F3]On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
Documents
Issuer
Intellia Therapeutics, Inc.
CIK 0001652130
Entity typeother
Related Parties
1- filerCIK 0001810882
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 8:33 PM ET
- Size
- 7.7 KB